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METHODS: Patients received twice-daily doses of tapentadol ER (100–250 mg), 
oxycodone HCl controlled release (CR; 20–50 mg), or placebo over a 15-week treat-
ment period. Patients completed the EQ-5D (evaluates mobility, self-care, usual activi-
ties, pain/discomfort, and anxiety/depression) at baseline and at prespeciﬁed time 
points. RESULTS: Efﬁcacy and safety were evaluated for 1,023 patients who received 
q1 dose of study medication. Overall, the change from baseline in the EQ-5D health 
status index was signiﬁcantly greater with tapentadol ER versus both oxycodone CR 
and placebo (least squares mean difference [95% conﬁdence interval] between tapen-
tadol ER and oxycodone CR, 0.07 [0.03,0.10; P  0.001]; between tapentadol ER 
and placebo, 0.05 [0.02,0.09; P  0.004]). Differences between oxycodone CR and 
placebo were not signiﬁcant (−0.01 [−0.05,0.02; P  0.449]). Across all treatment 
groups at baseline, the percentages of patients reporting no problems in each of 
the EQ-5D dimensions were as follows: mobility, 9%–10%; self-care, 77%–82%; 
usual activities, 14%–17%; pain/discomfort, 0%–1%; and anxiety/depression, 
68%–70%. At endpoint, the percentages of patients reporting no problems 
were mobility: placebo, 16.3%; tapentadol ER, 25.0%; oxycodone CR, 16.7%; 
self-care: placebo, 75.1%; tapentadol ER, 81.1%; oxycodone CR, 80.1%; usual 
activities: placebo, 26.1%; tapentadol ER, 33.7%; oxycodone CR, 27.2%; pain/
discomfort: placebo, 5.6%; tapentadol ER, 9.0%; oxycodone CR 4.7%; and anxiety/
depression: placebo, 71.8%; tapentadol ER, 70.9%; oxycodone CR, 69.6%. A total 
of 61.1%, 75.9%, and 87.4% of patients who received placebo, tapentadol ER, and 
oxycodone CR, respectively, reported q1 treatment-emergent adverse event. CON-
CLUSIONS: Treatment with tapentadol ER (100–250 mg bid) signiﬁcantly improved 
overall health status compared with placebo and oxycodone HCl CR (20–50 mg bid) 
in patients with moderate to severe chronic osteoarthritis knee pain.
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OBJECTIVES: The aim of the current study was to compare the efﬁcacy of pharma-
cological treatments for the management of ﬁbromyalgia with particular focus on 
outcomes considered most important by the Outcome Measures in Rheumatoid 
Arthritis Clinical Trials (OMERACT) symposium. METHODS: A systematic review 
was conducted to identify randomised controlled trials (RCTs) evaluating pharmaco-
logical treatments in adults with ﬁbromyalgia. A Bayesian MTC was performed in 
WinBUGS to estimate the relative efﬁcacy of the evaluated treatments. The primary 
efﬁcacy outcome was the absolute reduction in pain score at study endpoint, based 
on visual analogue or numerical rating scales. Secondary efﬁcacy outcomes included 
proportion of patients responding, changes in Fibromyalgia Impact Questionnaire 
(FIQ) total score, sleep and quality of life measures. Random-effects models were used 
to account for any heterogeneity; ﬁxed-effects models were evaluated in sensitivity 
analysis. RESULTS: Eleven RCTs were included in the review, with 21 RCTs meeting 
criteria for inclusion in the meta-analysis (ﬁxed-dosing regimen, parallel-group study 
design, and high quality [Jadad score q3]). Ten RCTs reported data on the primary 
outcome measure suitable for inclusion in the MTC. These trials evaluated nine treat-
ment regimens: alprazolam, citalopram, duloxetine, ibuprofen, milnacipran, parox-
etine, placebo, pregabalin, ibuprofen  alprazolam. Results from a random-effects 
MTC found that only pregabalin 300, 450, 600 mg/day and duloxetine 20, 60, 
120 mg/day produced signiﬁcantly greater reductions in pain score (p  0.05) than 
placebo. Duloxetine 120 mg/day was signiﬁcantly superior to citalopram 20 mg/day 
and milnacipran 100 mg/day (p  0.05), with no other statistically signiﬁcant differ-
ences reported between active treatments. CONCLUSIONS: Only 21 studies met the 
inclusion criteria for the MTC reﬂecting the relatively poor quality of the majority of 
published studies. Of the treatments included in the MTC of the primary outcome, 
only pregabalin and duloxetine were signiﬁcantly superior to placebo for pain relief.
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OBJECTIVES: Cost-effectiveness models of biologic treatments for RA have been 
shown to be strongly affected by improved physical function, as measured by HAQ-
DI. This analysis was conducted to focus on patients receiving continuous treatment 
with tocilizumab (TCZ) 8 mg/kg monthly and conventional anti-rheumatic medica-
tions for more than 24 weeks, while assessing HAQ-DI scores. METHODS: HAQ-DI 
scores in patients with moderate to severe RA were obtained from the 8-mg/kg treat-
ment groups of three extension studies of four randomised, placebo-controlled studies. 
Analysis focused on observations at or after week 24 to assess the long-term effects 
of treatment. Week 192 was chosen as a cut-off to preserve sufﬁcient sample size. 
Analysis of mean HAQ-DI scores (average at each time window) was conducted for 
all observations. Parallel analysis was conducted separately for patients who received 
previous therapy with anti-TNF agents that did or did not fail. A trendline was ﬁtted 
to the data to describe the overall trend and assess its linearity. In addition, a mixed 
linear model of HAQ-DI as a function of time was estimated at the patient level. 
RESULTS: A total of 1422 patients were available at week 24. Nearly 40% (546) 
have been observed through week 156, and 56 have been observed through week 192. 
All-observed analysis showed a strong linear relationship with a slow, steady decrease 
in HAQ-DI scores through week 192 (week 24  1.05; week 192  0.88; slope  
0.015; R2  0.87). HAQ-DI improvement was monotonic through week 156. Strati-
ﬁcation by previous failure of anti-TNF therapy produced similar ﬁndings. Patient-
level mixed-model results were consistent, showing a signiﬁcant downward slope. 
CONCLUSIONS: Patients with RA treated with 8 mg TCZ in combination with 
standard anti-rheumatic medications have steadily improving HAQ-DI scores while 
on treatment through week 192. Cost-effectiveness models of TCZ should include 
these ﬁndings to accurately gauge the utility of treatment.
PMS7
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OBJECTIVES: To compare dosing patterns between duloxetine and pregabalin among 
patients with ﬁbromyalgia. METHODS: Using a large US administrative claims data-
base, we examined commercially insured individuals aged 18–64 with ﬁbromyalgia 
who initiated duloxetine or pregabalin in 2006. Initiation was deﬁned as 90-day 
medication gap, with the dispense date of the ﬁrst initiation as the index date. All 
patients included had 12-month continuous enrollment in the pre- and post-index 
period, and at least 30 days supply of duloxetine or pregabalin in the 12 months 
post-index period. Patients with diabetic peripheral neuropathic pain or depression in 
the 12 months pre-index period were excluded. Duloxetine or pregabalin cohorts were 
constructed based on the index agent. Average daily doses of all duloxetine or prega-
balin prescriptions per person, average daily dose in each of the ﬁrst 12 prescriptions, 
and percent of daily dose change from previous prescription were compared between 
duloxetine and pregabalin cohorts. RESULTS: Both the duloxetine (n  3773) and 
pregabalin (n  4189) cohorts had the mean age of 50 years. The duloxetine cohort 
had an average initial daily dose of 55.7 mg, while 161.5 mg for the pregabalin cohort. 
The average daily dose per patient was 55.5 mg for duloxetine and 195.7 mg for pre-
gabalin. The average daily doses for the ﬁrst through twelfth duloxetine scripts varied 
from 55.68 mg (95% Conﬁdence Interval (CI): 54.96, 56.40) to 60.34 mg (95% CI: 
54.71, 65.97), while the numbers were 161.50 mg (95% CI: 159.02, 163.98) and 
282.41 mg (95% CI: 266.89, 297.93) for pregabalin. The percentages of changes in 
daily dose from previous prescriptions were 4.2^1.6% for duloxetine and 1.3^14.3% 
for pregabalin, respectively. CONCLUSIONS: Among patients with ﬁbromyalgia, 
duloxetine and pregabalin initiators had very different dosing patterns. The average 
daily dose for duloxetine was relatively stable over time, while pregabalin patients had 
signiﬁcant dose escalation over the 12-month follow-up period.
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OBJECTIVES: To assess the estimated prevalence of ﬁbromyalgia sufferers in Russia          
among the general adult population. METHODS: To The validated Russian version     
of the screening questionnaire was administrated to a representative community 
sample (n  1610), deﬁned by IPSOS® according to the quotas method (sex, age, 
householder’s profession) with a stratiﬁcation according to the region / cities commu-
nity. The LFESSQ questionnaire allows to screen patients who might have ﬁbromyal-
gia. The LFESSQ questionnaire allows to screen patients who might have ﬁbromyalgia.            
A positive screen was deﬁned as: meeting the 4-pain criteria alone (LFESSQ-4), or 
meeting both the 4-pain and 2-fatigue criteria (LFESSQ-6). The questionnaire was 
submitted to a sample of rheumatology outpatients (n  399), who were then examined 
by a trained rheumatologist to conﬁrm or exclude the diagnosis of FM according to 
the 1990 American College of Rheumatology criteria. The prevalence of FM in the 
general population was estimated by applying the predictive positive value to eligible 
community subjects (i.e., positive screens). RESULTS: The community sample is con-    
stituted of 885 females and 725 men. 20.1% screened positive for LFESSQ-4 (25.3% 
in females and 13.7% in males respectively). A total of 13.8% screened positive for 
LFESSQ-6 (18.4% in females and 8.1% in males, respectively). Among rheumatology 
outpatients, 43.6% were screened positive for LFESSQ-6 (44.3% in females and 
40.5% in males, respectively), whereas 6.5% were conﬁrmed FM cases (ACR criteria). 
The prevalence of FM was estimated at 2.1% (95% CI: 1.4%–2.8%, 2.8% in females 
and 1.2% in males respectively) in the Russian general population. CONCLUSIONS: 
Our ﬁndings are in agreement with those of earlier national survey reports and previ-
ous publications in US, Canada and Spain. A point prevalence of 2.1 % would trans-
late in approximately 2.5 million of patients with FM in Russia.
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OBJECTIVES: Secular decreases in hip fracture rates have been reported in some 
countries. Whether this phenomenon applies to other fracture sites has not been 
studied. Our objective was to examine fracture patterns across twenty years in a 
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population-based cohort to inform health care planners on trends in costs and resource 
needs related to fractures. METHODS: We used the Population Health Research Data 
Repository for the Province of Manitoba, Canada which is a comprehensive collection 
of databases including physician visits, hospitalizations and pharmaceutical prescrip-
tions. Age and sex-adjusted fracture rates were calculated for men and women age 
ﬁfty years and older from 1986 to 2006 according to fracture site (deﬁned by ICD-9-
CM codes) and mechanism (presence/absence of ICD-9-CM external injury codes). 
Generalized linear models with generalized estimating equations were used to derive 
adjusted annual rates and test the linear change overall, and for men and women 
separately. RESULTS: Osteoporotic fractures (non-traumatic fractures of the hip, 
forearm, spine and humerus) showed a signiﬁcant linear decline (0.8% per-annum 
[95% CI 0.3–1.2%]), with a greater decline in women (1.0% [0.4–1.7%]) than in 
men (0.5% [0.0–1.3%], P  .05 for sex interaction). Similar trends were seen for all 
fractures sites: hip 0.9% (0.2–1.7%), forearm 0.8% (0.4–1.3%), humerus (0.7% 
[0.2–1.2%]) and spine (0.5% [0.0–1.0%]) A greater reduction in traumatic fractures 
was observed (1.8% per-annum [95% CI 1.0–2.6%]), with a greater decline in men 
(2.2% [1.3–3.1%]) than in women (1.3% [0.2–2.4%], P  .05 for sex interaction). 
Similar results were seen when testing the difference between the initial 5 years 
(1986–1991) and the ﬁnal ﬁve years (2001–2006) of data. CONCLUSIONS: We 
observed a decrease in both non-traumatic (osteoporotic) and traumatic fracture rates 
over the study period. This decline was apparent in years prior to widespread osteo-
porosis testing or availability of modern pharmacotherapy.
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OBJECTIVES: It has been reported that bone fracture the risk of developing increases 
for patients who had fractures once before, and and that such patients do not receive 
enough osteoporosis treatment. In this present study, we investigated incidence of 
recurrent fractures and the circumstances of pharmacotherapy for osteoporosis among 
patients who had experience ﬁrst hip fracture. METHODS: Female patients 65 years 
and older who had experienced ﬁrst hip fractures from January 1, 2006 to December 
31, 2007 were enrolled at 25 hospitals.We reviewed their medical records and con-
ducted a patient survey to collect information on surgical methods, osteoporosis 
treatments and prognosis for 1 year after ﬁrst hip fracture.The questionnaires were 
ﬁlled out by either the patient or family member. This interim analysis was conducted 
for 477 patients of 7 hospitals out of 2,266 enrolled patients. RESULTS: The average 
age was 84.0 (66–103) years old. In terms of fracture type, we identiﬁed 237 cervical 
cases and 237 intertrochantric fractures, with 3 cases that were not speciﬁed. A total 
of 94.3 % of the patients received an operation. During hospitalization, 26.2% were 
on pharmacotherapy and 22.9% received no pharmacotherapy. For the observational 
period, 1 year after ﬁrst fractures, 13.4% of the patients received pharmacotherapy, 
but 57.2% received no treatment. For the observational period, 44 patients (9.2%) 
experienced recurrent fractures and 18 (3.8%) out of those suffered hip fractures. 
CONCLUSIONS: In this study, the incidence of recurrent hip fractures among patients 
who have already experienced a ﬁrst hip fracture was 3,800/100,000 person-year. This 
is 7.4 times the rate found in the general population of the same age group. Despite 
this increase in incidence rate, only 13% of patients had received osteoporosis treat-
ment after the ﬁrst hip fracture. Japanese patients who have already suffered from a 
ﬁrst hip fracture must be considered high risk patients who should be treated with 
preventive action.
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OBJECTIVES: Osteoporosis is characterized by low bone mass and increased fracture 
risk. Increased mortality rates have been documented following fractures, particularly 
hip and vertebral. Our aim was to compare short-term and long-term mortality rates 
following an incident fracture in men and women at different sites (hip, wrist, spine, 
humerus and others). METHODS: We identiﬁed a population-based cohort of men 
and women with non-traumatic incident fractures between 1986 and 2006 within the 
hospital, physician and pharmacy administrative database repository of the Province 
of Manitoba, Canada. The cohort-entry date was the date of a ﬁrst fracture (index 
fracture) after age 50 years. Two matched controls from the same databases were 
identiﬁed for each case. Crude and adjusted mortality rates for each fracture site were 
computed separately for men and women. Secular trends in fracture site-speciﬁc mor-
tality rates over the study period were tested using generalized linear models. 
RESULTS: We identiﬁed 23,514 index fractures in men and 52,897 in women. The 
crude mortality rates were consistently higher in men compared to women. Highest 
ﬁrst year mortality rates were noted after hip (women 20.1% vs. men 33.6%) followed 
by spine fractures (13.9% vs. 15.8%), with lower mortality rates after humerus (7.4% 
vs. 15.3%), wrist (3.4% vs. 5.3%) and other fractures (9.2% vs. 11.0%). Similar 
rankings by fracture site were seen for year ﬁve mortality: hip fractures (women 53.1% 
vs. men 66.7%) followed by spine (38.4% vs. 43.1%), humerus (26.6% vs. 41.2%), 
wrist (15.7% vs. 21.2%) and other fractures (26.5% vs. 29.3%). Post-fracture mortal-
ity rates were generally stable over the study period. CONCLUSIONS: Fractures at 
all sites are associated with signiﬁcant mortality rates, particularly in men. Better 
understanding of factors associated with increased post-fracture mortality will inform 
the development of practice guidelines and improved clinical outcomes.
MUSCULAR-SKELETAL DISORDERS – Cost Studies
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PROBABILISTIC ANALYSIS OF BUDGETARY IMPACT: GLUCOSAMINE 
IN KNEE OSTEOARTHRITIS TREATMENT
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OBJECTIVES: To determine the ﬁnancial impact of inclusion of glucosamine in the 
hospital formulary of Petchabun Hospital. METHODS: Conventional NSAIDs, cele-
coxib, glucosamine were included in the analysis. Hospital perspective was used and 
we considered only patients who failed to control pain by acetaminophen. Treatment 
cost of GI and CV event was calculated based on decision tree model in which cooper-
ated with probability from the literature and local DRG cost data. Average cost of 
drug use per patient per year was calculated from the medical history and computer-
ized dispensing data. Delphi technique with all treating orthopaedics was used to 
obtain the estimates of number of patient eligible for glucosamine use and effect on 
volume of other drugs’ use in the following years. Probabilistic analysis was used to 
capture the certainties around estimations. We analyzed this data in a 5-year timeframe 
(2005–2009) as we assumed the steady penetration of glucosamine was reached. 
RESULTS: In 2005, we estimated there was an increase in drug budget for knee 
osteoarthritis treatment around 0.8 million baht (23,000 US$) which was growing 
from 2004 at 7%; it was similar to the growth rate in the ealier year. This was mainly 
due to the expected reduction in NSAIDs and coxib uses. The forecast budget impact 
in 2006–2009 were about 0.8, 0.6, 0.5, and 0.2 million baht at the growth rate 6.2%, 
4.4%, 3.5% , and 1.5%respectively. Cost of glucosamine was found to be the most 
sensitive variable, followed by cost of celecoxib and number of patients using glucos-
amine. CONCLUSIONS: Hospital administrators found that glucosamine use resulted 
in an affordable ﬁnancial burden to the drug budget for knee osteoarthritis in the 
hospital. However, to ensure the effective use of glucosamine, they developed the 
guideline for glucosamine use and also monitor the clinical and economic outcomes. 
Updated analyses were also recommended to obtain the reliable information for 
budget planning in the following years.
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OBJECTIVES: Gout is a chronic condition caused by hyperuricemia, a metabolism 
and excretion disorder characterized by intense pain “ﬂares” in affected joints. The 
objective was to estimate budgetary impact of adding febuxostat to a US health plan 
formulary for gout treatment. METHODS: An interactive model was developed using 
decision analysis methods comparing expected annual number of gout ﬂares and 
associated costs among members treated with febuxostat 40 mg/80 mg vs allopurinol 
300 mg for 1 year. Underlying model data and default inputs were obtained from 
clinical trials, retrospective studies, and published literature. Gout prevalence was 1%, 
among which 34% were estimated to be treated. Average febuxostat 1-year market 
share was assumed to be 3.9%. Model outputs included total per-member per-month 
(PMPM) cost; gout-, tophi-, and ﬂare-related medical costs and total pharmacy costs, 
and number needed to treat (NNT). Costs were adjusted to 2008 $US. User-modiﬁed 
sensitivity analysis on gout prevalence, ULT market share, and pharmacy cost was 
conducted. RESULTS: In a hypothetical 1-million-member health plan, adding febux-
ostat 40 mg/80 mg to the formulary is expected to increase total annual cost by $0.008 
PMPM, reduce gout-related costs by $26,010, and increase pharmacy costs by 
$124,494. Model data projected a reduction of 22 ﬂares when adding febuxostat to 
the formulary and NNT of 6.25 patients on febuxostat to prevent 1 gout ﬂare. Sensi-
tivity analyses indicate a positive relationship between febuxostat market share and 
gout ﬂares avoided and gout-related medical costs. CONCLUSIONS: This robust 
model evaluates the 1-year pharmacy and medical cost offsets on total payer budget. 
Adding a new ULT to a US health plan formulary minimally impacts total payer 
budget as shown by the marginal PMPM cost increase and signiﬁcant gout-related 
medical savings.
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MODELING THE PROGRESSION OF RHEUMATOID ARTHRITIS IN 
ITALY: BUDGET IMPACT ANALYSIS FOR BIOLOGIC AGENTS
Di Matteo S, Colombo GL
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OBJECTIVES: Two simulation models were developed to analyze the cost and out-          
comes of the biological agents currently marketed in Italy vs disease-modifying anti-
rheumatic drugs (DMARDs) that affect the progression of rheumatoid arthritis (RA). 
METHODS: A Markov model over 10 years was constructed with four disease states            
according to functional status (HAQ). Disease progression (transition probabilities 
between the states) was taken from clinical trial data and published literature. Patient 
